MMCAP International Inc. SPC bought a new position in Profound Medical Corp. (NASDAQ:PROF - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 490,000 shares of the company's stock, valued at approximately $3,680,000. MMCAP International Inc. SPC owned approximately 1.63% of Profound Medical at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Profound Medical in the 3rd quarter worth $612,000. Gagnon Securities LLC increased its holdings in shares of Profound Medical by 12.6% in the 4th quarter. Gagnon Securities LLC now owns 1,652,531 shares of the company's stock worth $12,411,000 after purchasing an additional 185,284 shares in the last quarter. Gagnon Advisors LLC increased its holdings in shares of Profound Medical by 20.0% in the 4th quarter. Gagnon Advisors LLC now owns 896,671 shares of the company's stock worth $6,734,000 after purchasing an additional 149,445 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Profound Medical by 0.6% in the third quarter. Royce & Associates LP now owns 569,298 shares of the company's stock worth $4,529,000 after acquiring an additional 3,500 shares during the period. Finally, MTM Investment Management LLC grew its holdings in shares of Profound Medical by 10.4% in the fourth quarter. MTM Investment Management LLC now owns 18,575 shares of the company's stock worth $139,000 after acquiring an additional 1,750 shares during the period. Institutional investors own 47.86% of the company's stock.
Profound Medical Stock Performance
Shares of PROF traded down $0.22 during trading hours on Friday, hitting $6.93. The stock had a trading volume of 52,791 shares, compared to its average volume of 80,202. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.12 and a quick ratio of 5.16. Profound Medical Corp. has a 12 month low of $5.63 and a 12 month high of $11.42. The firm has a market capitalization of $208.18 million, a PE ratio of -5.17 and a beta of 0.88. The stock has a fifty day moving average price of $7.01 and a 200 day moving average price of $7.67.
Analyst Ratings Changes
Separately, Raymond James raised Profound Medical to a "strong-buy" rating in a report on Saturday, November 9th.
Read Our Latest Analysis on PROF
About Profound Medical
(
Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Featured Articles
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
